Results 71 to 80 of about 44,151 (306)

Metabolomic profiling of cellular responses to carvedilol enantiomers in vascular smooth muscle cells. [PDF]

PLoS ONE, 2010
Carvedilol is a non-selective β-blocker indicated in the treatment of hypertension and heart failure. Although the differential pharmacological effects of individual Carvedilol enantiomer is supported by preceding studies, the cellular response to each ...
Mingxuan Wang, Jing Bai, Wei Ning Chen, Chi Bun Ching   +3 more
doaj   +1 more source

Synthesis and Characterization of Carvedilol-Etched Halloysite Nanotubes Composites with Enhanced Drug Solubility and Dissolution Rate

Molecules, 2023
Carvedilol is a poorly water-soluble drug employed to treat chronic heart failure. In this study, we synthesize new carvedilol-etched halloysite nanotubes (HNTs) composites to enhance solubility and dissolution rate.
Lauretta Maggi, Claudia Urru, Valeria Friuli, Chiara Ferrara, Debora Maria Conti, Giovanna Bruni, Doretta Capsoni   +6 more
doaj   +1 more source

Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF) [PDF]

, 2014
Aim<p></p> To describe the baseline characteristics and treatment of the patients randomized in the PARADIGM-HF (Prospective comparison of ARNi with ACEi to Determine Impact on Global Mortality and morbidity in Heart Failure) trial, testing ...
Adel R. Rizkala, Akshay S Desai, Jean L. Rouleau, Jianjian Gong, John J. V. McMurray, Karl Swedberg, Martin Lefkowitz, Michael R. Zile, Milton Packer, null null, Scott D. Solomon, Victor C. Shi   +11 more
core   +2 more sources

Carvedilol induces biased β1 adrenergic receptor-Nitric oxide synthase 3-cyclic guanylyl monophosphate signaling to promote cardiac contractility.

Cardiovascular Research, 2020
AIMS β-blockers are widely used in therapy for heart failure and hypertension. β-blockers are also known to evoke additional diversified pharmacological and physiological effects in patients.
Qingtong Wang, Ying Wang, Toni M West, Yongming Liu, G. Reddy, F. Barbagallo, Bing Xu, Qian Shi, Bingqing Deng, Wei Wei, Y. Xiang   +10 more
semanticscholar   +1 more source

Tailoring therapy for heart failure: the pharmacogenomics of adrenergic receptor signaling. [PDF]

, 2014
Heart failure is one of the leading causes of mortality in Western countries, and β-blockers are a cornerstone of its treatment. However, the response to these drugs is variable among individuals, which might be explained, at least in part, by genetic ...
Barrese, V, Femminella, GD, Ferrara, N, Rengo, G   +3 more
core   +2 more sources

Hepatotoxicity Associated with Carvedilol [PDF]

American Journal of Pharmacology and Pharmacotherapeutics, 2018
Objective: The serum transaminases document is severe elevated in a patient who was receiving Carvedilol. Case Summary: A 65-year-old Saudi man admitted to hospital with acute heart failure (EF 15%), acute liver failure and acute kidney injury. He was admitted to CCU and started treatment.
openaire   +3 more sources

Nephroprotective Effect of Pleurotus ostreatus and Agaricus bisporus Extracts and Carvedilol on Ethylene Glycol-Induced Urolithiasis: Roles of NF-κB, p53, Bcl-2, Bax and Bak

Biomolecules, 2020
This study was designed to assess the nephroprotective effects of Pleurotus ostreatus and Agaricus bisporus aqueous extracts and carvedilol on hyperoxaluria-induced urolithiasis and to scrutinize the possible roles of NF-κB, p53, Bcl-2, Bax and Bak ...
O. Ahmed, H. Ebaid, El-Shaymaa El-Nahass, M. Ragab, I. Alhazza   +4 more
semanticscholar   +1 more source

Ivabradine could not decrease mitral regurgitation triggered atrial fibrosis and fibrillation compared with carvedilol

ESC Heart Failure
Background Ivabradine, a medical treatment for heart failure (HF), reduces heart rate (HR) and prolongs diastolic perfusion time. It is frequently prescribed to patients with HF who have a suboptimal response or intolerance to beta‐blockers. Degenerative
Wei‐Chieh Lee, Yu‐Wen Lin, Jhih‐Yuan Shih, Zhih‐Cherng Chen, Nan‐Chun Wu, Wei‐Ting Chang   +5 more
doaj   +1 more source

Preventive effects of carvedilol on nitrate tolerance—a randomized, double-blind, placebo-controlled comparative study between carvedilol and arotinolol [PDF]

, 1998
Objectives. This study was designed to compare the preventive effect of nitrate tolerance between carvedilol with antioxidant properties and arotinolol without antioxidant properties.Background.
Kakihana, Masaaki, Ohtsuka, Sadanori, Sugishita, Yasuro, Watanabe, Hideki   +3 more
core   +1 more source

Carvedilol in Dogs with Dilated Cardiomyopathy [PDF]

Journal of Veterinary Internal Medicine, 2007
Background: Dilated cardiomyopathy (DCM) is characterized by reduced systolic function, heightened sympathetic tone, and high morbidity and mortality. Little is known regarding the safety and efficacy of ß‐blocker treatment in dogs with DCM.Hypothesis: Carvedilol improves echocardiographic and neurohormonal variables in dogs with DCM over a 4‐month ...
Barret J. Bulmer, D. David Sisson, Mike W. Luethy, Virginia Luis Fuentes, Robert A. Prosek, Mark A. Oyama   +5 more
openaire   +3 more sources